{"schema_version":"secwatch.filing_event.v1","accession":"0001606498-23-000067","form_type":"8-K","ticker":"AVNS","cik":"0001606498","company_name":"AVANOS MEDICAL, INC.","filed_at":"2023-08-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.533234+00:00","generated_at":"2026-06-11T22:20:11.059487+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Avanos clarifies Q2 2023 results beat consensus after third-party error","bullets":["Third party incorrectly reported Avanos missed consensus; total sales including discontinued RH business were $199.8M.","Adjusted diluted EPS including discontinued ops was $0.37, ahead of consensus.","Continuing operations: net sales $169.4M, diluted loss per share $0.09, adjusted EPS $0.24.","RH business operating results reported as discontinued operations due to planned divestiture."],"urls":{"canonical":"https://secwatch.observer/filing/0001606498-23-000067","json":"https://secwatch.observer/filing/0001606498-23-000067.json","markdown":"https://secwatch.observer/filing/0001606498-23-000067.md","text":"https://secwatch.observer/filing/0001606498-23-000067.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1606498/000160649823000067/0001606498-23-000067-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1606498/000160649823000067/avns-20230809.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T22:20:11.059487+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}